Your Search Results

EuroPCR 2026 Closing Ceremony

22 May 2026 – From EuroPCR 2026

The EuroPCR 2026 Closing Ceremony marks the conclusion of this premier cardiology event, celebrating the latest advances and achievements in interventional cardiology. It offers an opportunity to reflect on the educational sessions, network with peers, and recognize outstanding contributions to the field.

Welcome to EuroPCR 2026

19 May 2026 – From EuroPCR 2026

Welcome to EuroPCR 2026, the premier event for interventional cardiology professionals. This edition offers cutting-edge scientific presentations, live cases, and interactive sessions designed to advance knowledge and clinical practice in cardiovascular interventions.

Addressing difficult anatomy in STEMI patients

21 May 2026 – From EuroPCR 2026

This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.

Pharmacology without borders, from coronary artherostenosis to radial artery

21 May 2026 – From EuroPCR 2026

This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

18 Sep 2022

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Author

Jonathan Curio

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

Outcomes in patients with atrial fibrillation randomized to receive LAA closure or oral anticoagulation: Primary results of the CHAMPION-AF clinical trial

28 Mar 2026

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).